Nilotinib inhibition of HEI-193 cells decreases activation of PDGFR-α and PDGFR-β.

<p>HEI-193 cells inhibited with nilotinib and stimulated with PDGF-BB or GM were lysed and analyzed by Western immunoblot using phophorylation-specific antibodies. Comparison was made to total protein expression, as determined by immunoblotting using non-activation specific antibodies. Densitometry was used to evaluate fold-change in phosphorylation, with values normalized to activation in the presence of vehicle control. **denotes significant (<i>p</i><0.05) difference compared to phosphorylation in vehicle control. (A) PDGF-BB activation of both PDGFR-α and PDGFR-β is abrogated in the presence of ≥3 µM nilotinib. (B) GM-stimulated activation of PDGFR-β is inhibited by ≥3 µM nilotinib.